Lamp2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| | |
|---|---|
| Gene Symbol | LAMP2 |
| Full Name | Lysosomal Associated Membrane Protein 2 |
| Chromosomal Location | Xq24 (ChrX: 119,769,452-119,810,423) |
| NCBI Gene ID | 3990 |
| OMIM | 300256 |
| Ensembl ID | ENSG00000143106 |
| UniProt | P13473 |
LAMP2 encodes Lysosomal Associated Membrane Protein 2, a major lysosomal membrane glycoprotein essential for lysosomal function, autophagy, and chaperone-mediated autophagy (CMA).
- Lysosomal membrane integrity: Major structural protein
- Chaperone-mediated autophagy (CMA): Receptor for cytosolic proteins
- Macroautophagy: Involved in autophagosome-lysosome fusion
- Phagocytosis: Facilitates cellular debris clearance
- Cholesterol trafficking: Regulates cellular cholesterol homeostasis
- Type I transmembrane glycoprotein
- Large lumenal domain (N-terminal)
- Short cytoplasmic tail (C-terminal)
- Heavily glycosylated (N-linked glycans)
- Ubiquitously expressed
- Highest in liver, brain, heart, skeletal muscle
- In brain: neurons, astrocytes, microglia
- Three splice variants: LAMP2A (CMA), LAMP2B, LAMP2C
- X-linked dominant storage disorder
- Caused by LAMP2 mutations (typically nonsense/frameshift)
- Triad: cardiomyopathy, skeletal myopathy, intellectual disability
- Hypertrophic cardiomyopathy in males (often fatal)
- Presents in adolescence/young adulthood
- LAMP2A dysfunction implicated in PD pathogenesis
- Reduced CMA activity in PD brain
- Accumulation of autophagic substrates
- Interaction with alpha-synuclein metabolism
- LAMP2 decreases with aging and AD
- Impaired autophagic-lysosomal pathway in AD
- Role in Aβ and tau clearance
- Potential therapeutic target
- Altered LAMP2 expression in ALS
- Autophagy dysregulation in motor neurons
- May modify disease progression
- Danon disease shares features with other LSDs
- May have overlapping therapeutic approaches
- AAV-LAMP2B being developed for Danon disease
- Studies in mouse models show promise
- Autophagy-enhancing compounds
- CMA modulators in development
- Investigational recombinant LAMP2 protein
- Challenges: delivery to lysosomes
- PMID 10827078 - Discovery of LAMP2 and Danon disease
- PMID 15681606 - LAMP2 in autophagy
- PMID 19052770 - Chaperone-mediated autophagy
- PMID 23393156 - LAMP2 in Parkinson's disease
- PMID 35225893 - Gene therapy for Danon disease
The study of Lamp2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
LAMP2 (Lysosomal-Associated Membrane Protein 2) expression patterns:
- Hippocampus - High expression in pyramidal neurons
- Cerebral cortex - High expression in layer 5 neurons
- Substantia nigra - Moderate-high expression in dopaminergic neurons
- Heart - High expression (relevant for Danon disease)
LAMP2 is expressed in:
- Neurons (pyramidal cells)
- Dopaminergic neurons
- Cardiomyocytes
- All cell types (ubiquitous lysosomal protein)
| Region |
Expression Level |
Data Source |
| Hippocampus |
High |
Mouse Brain |
| Cortex |
High |
Mouse Brain |
| Substantia nigra |
Medium-High |
Mouse Brain |
| Cerebellum |
Medium |
Mouse Brain |
| Striatum |
Medium |
Mouse Brain |